Stockscreener 앱 받기
6.25
0.64%
0.04
전일 마감가:
$6.21
열려 있는:
$6.21
하루 거래량:
1.19M
Relative Volume:
0.83
시가총액:
$458.34M
수익:
-
순이익/손실:
$-56.17M
주가수익비율:
-3.478
EPS:
-1.797
순현금흐름:
$-39.99M
1주 성능:
+1.63%
1개월 성능:
+43.35%
6개월 성능:
+308.50%
1년 성능:
+1,983%
1일 변동 폭
$5.93
$6.315
1주일 범위
$5.82
$6.555
52주 변동 폭
$0.243
$7.51
Relmada Therapeutics Inc Stock (RLMD) Company Profile
명칭
Relmada Therapeutics Inc
전화
646 876 3459
주소
2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY
Compare RLMD vs MOBBW, PSNYW, GOODO, SHMD, DWLD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| 3.03 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
2.52 | 3.71B | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
4.58 | 414.42M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
GOODO
Gladstone Commercial Corporation
|
19.91 | 372.90M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
6.52 | 377.54M | 52.15M | -21.46M | 0 | -0.4675 |
|
DWLD
Davis Select Worldwide ETF
|
43.90 | 0 | 0 | 0 | 0 | 0.00 |
Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-23 | 재개 | Leerink Partners | Outperform |
| 2025-12-22 | 개시 | Jefferies | Buy |
| 2025-11-19 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2024-12-05 | 다운그레이드 | Mizuho | Outperform → Neutral |
| 2024-09-17 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-06-05 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-10-14 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-10-14 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-10-14 | 다운그레이드 | Truist | Buy → Hold |
| 2022-10-13 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-11-18 | 개시 | Mizuho | Buy |
| 2021-05-20 | 재개 | Goldman | Buy |
| 2020-10-28 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-07-14 | 개시 | Oppenheimer | Outperform |
| 2020-05-04 | 개시 | SunTrust | Buy |
| 2020-04-21 | 개시 | Goldman | Buy |
| 2020-01-27 | 개시 | Jefferies | Buy |
| 2020-01-10 | 개시 | SVB Leerink | Outperform |
| 2019-12-16 | 개시 | Guggenheim | Buy |
모두보기
Relmada Therapeutics Inc 주식(RLMD)의 최신 뉴스
Earnings call transcript: Relmada Therapeutics Q4 2025 shows EPS miss, stock stable - Investing.com
RLMD: NDV-01 delivers high response rates in NMIBC, with Phase 3 trials and strong financial runway ahead - TradingView
RLMD: NDV-01 achieved durable, high response rates with favorable safety in high-risk NMIBC - TradingView
Relmada Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Relmada Therapeutics 10-K: $0 Revenue, $(1.45) EPS on $(57.39)M Net Loss - TradingView
Relmada (NASDAQ: RLMD) pivots to NDV-01 cancer drug and sepranolone - Stock Titan
RLMD: Strong NDV-01 clinical results and $160M financing support Phase 3 launch and extended cash runway - TradingView
Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update - The Manila Times
BRIEF-Relmada Therapeutics Q4 EPS USD -0.27 - TradingView
Bladder cancer drug shows 76% response at 12 months as Relmada readies Phase 3 - Stock Titan
Lucid Capital Markets initiates coverage of Relmada Therapeutics (RLMD) with buy recommendation - MSN
Relmada’s Withdrawn Phase 3 Bladder Cancer Trial: What It Means for RLMD Investors - TipRanks
Relmada’s Withdrawn BOOST Trial Resets Expectations for NDV-01 and RLMD - TipRanks
50% and 61% Gains in a Single Day: Why XENE and RLMD Soared Today - AOL.com
Analysts’ Top Healthcare Picks: Gain Therapeutics (GANX), Relmada Therapeutics (RLMD) - The Globe and Mail
Short Interest in Relmada Therapeutics, Inc. (NASDAQ:RLMD) Drops By 24.8% - MarketBeat
Mizuho reiterates Relmada stock rating on positive cancer trial data By Investing.com - Investing.com Australia
Mizuho reiterates Relmada stock rating on positive cancer trial data - Investing.com
Mizuho Reiterates Outperform Rating on Relmada Therapeutics Inc (RLMD): pullback 'a buying opprotunity' - StreetInsider
Relmada Therapeutics (RLMD) Projected to Post Earnings on Thursday - MarketBeat
RLMD Stock Soars Pre-Market: Phase 2 Bladder Cancer Trial Data Impresses Investors - MSN
Why Relmada Therapeutics (RLMD) Is Up 38.8% After $160M Raise And Positive NDV-01 Phase 2 Data - Yahoo Finance
RLMD stock surges 42% in a week: Here's what you should know - MSN
Relmada Therapeutics, Inc. announced that it has received $159.999996 million in funding from a group of investors - marketscreener.com
RLMD Stock Surges 42% in a Week: Here's What You Should Know - sharewise.com
RLMD Shares Jump 42% Over the Past Week: Key Information You Need - Bitget
Relmada reports 76% response rate for bladder cancer therapy - Investing.com Nigeria
Relmada Therapeutics to Report Fourth Quarter 2025 Financial Results on Thursday, March 19, 2026 - The Manila Times
Biotech Relmada schedules March 19 call on Q4 2025 results - Stock Titan
Should I buy Relmada Therapeutics (RLMD) - Zacks Investment Research
Relmada Therapeutics secures $160M in PIPE financing - Investing.com Nigeria
Relmada Therapeutics to Present at the Leerink Partners Global Healthcare Conference - 富途牛牛
Relmada Therapeutics (NASDAQ:RLMD) Shares Gap DownTime to Sell? - MarketBeat
Relmada Therapeutics at Leerink Global: Strategic Shift to Uro-Oncology By Investing.com - Investing.com Canada
A Look At Relmada Therapeutics (RLMD) Valuation After NDV-01 Phase 2 Update And US$160 Million Private Placement - Yahoo Finance
Relmada’s NDV-01 shows strong 12-month results in hard-to-treat bladder cancer - Indian Pharma Post
Relmada Therapeutics reports 12-month Phase 2 interim data for NDV-01 - TipRanks
Relmada reports 76% response rate for bladder cancer therapy By Investing.com - Investing.com Canada
Relmada Therapeutics secures $160M in PIPE financing By Investing.com - Investing.com Canada
Relmada Therapeutics (RLMD) Stock Jumps 31% on Breakthrough Bladder Cancer Data - MEXC
Relmada CEO and CFO head to Miami for Leerink fireside chat, investor meetings - Stock Titan
Relmada Therapeutics (NASDAQ:RLMD) Reaches New 12-Month HighShould You Buy? - MarketBeat
Relmada Therapeutics Announces 76% 12-Month Complete Response Rate in Phase 2 NDV-01 Trial for High-Risk Non-Muscle Invasive Bladder Cancer - Minichart
Biotech Stocks To Add to Your WatchlistMarch 9th - MarketBeat
Relmada Therapeutics shares jump 25% after promising bladder cancer trial results - MSN
Mizuho reiterates Relmada stock rating on bladder cancer trial data By Investing.com - Investing.com UK
Relmada Therapeutics Shares Surge 40.8% on Promising Trial Data - Intellectia AI
Relmada Therapeutics Gains Attention with Promising Bladder Cancer Asset - timothysykes.com
Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing - Investing News Network
Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer - Investing News Network
Relmada Therapeutics (RLMD) Stock Surges as Bladder Cancer Trial Shows 76% Response Rate - MEXC
Relmada Therapeutics Inc (RLMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Relmada Therapeutics Inc 주식 (RLMD) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Shenouda Maged | Chief Financial Officer |
Dec 15 '25 |
Buy |
4.12 |
11,665 |
48,060 |
800,000 |
| Shenouda Maged | Chief Financial Officer |
Nov 05 '25 |
Buy |
2.20 |
500,000 |
1,100,000 |
788,335 |
| Ence Chuck | CAO and COO |
Nov 05 '25 |
Buy |
2.20 |
136,000 |
299,200 |
403,931 |
| TRAVERSA SERGIO | Chief Executive Officer |
Nov 05 '25 |
Buy |
2.20 |
272,500 |
599,500 |
1,272,500 |
| Kelly Paul Edward | Chief Operating Officer |
Nov 05 '25 |
Buy |
2.20 |
90,000 |
198,000 |
502,295 |
| TRAVERSA SERGIO | Chief Executive Officer |
Aug 27 '25 |
Buy |
0.67 |
129,455 |
86,735 |
944,024 |
| TRAVERSA SERGIO | Chief Executive Officer |
Aug 26 '25 |
Buy |
0.62 |
80,545 |
49,938 |
814,569 |
| TRAVERSA SERGIO | Chief Executive Officer |
Aug 28 '25 |
Buy |
0.74 |
55,976 |
41,422 |
1,000,000 |
| Kelly Paul Edward | Chief Operating Officer |
May 16 '25 |
Buy |
0.43 |
200,000 |
86,060 |
412,295 |
| Shenouda Maged | Chief Financial Officer |
May 19 '25 |
Buy |
0.49 |
90,000 |
43,686 |
228,335 |
1.20%
0.06%
자본화:
|
볼륨(24시간):